PROKIDNEY CP (PROK)
(Delayed Data from NSDQ)
$1.70 USD
+0.14 (9.00%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.70 +0.01 (0.29%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for ProKidney Corp falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 363 | 490 | 0 | 0 | -99,999 |
Receivables | 1 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 10 | 14 | 1 | 0 | NA |
Total Current Assets | 374 | 505 | 1 | 0 | NA |
Net Property & Equipment | 42 | 11 | 0 | 0 | NA |
Investments & Advances | 0 | 0 | 250 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 0 | 0 | 0 | 0 | NA |
Total Assets | 421 | 518 | 251 | 0 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 5 | 3 | 0 | 0 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 18 | 7 | 2 | 0 | NA |
Income Taxes Payable | 1 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 25 | 11 | 2 | 0 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 1 | 0 | 258 | 0 | NA |
Minority Interest (Liabilities) | 1,495 | 1,602 | 0 | 0 | NA |
Total Liabilities | 1,524 | 1,615 | 260 | 0 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 36 | 7 | 0 | 0 | NA |
Retained Earnings | -1,140 | -1,104 | -8 | 0 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | -1,103 | -1,097 | -8 | 0 | NA |
Total Liabilities & Shareholder's Equity | 421 | 518 | 251 | 0 | NA |
Total Common Equity | -1,103 | -1,097 | -8 | 0 | 0 |
Shares Outstanding | 228.10 | 25.60 | 25.60 | NA | NA |
Book Value Per Share | -4.84 | -42.84 | -0.33 | 0.00 | 0.00 |
Fiscal Year End for ProKidney Corp falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 432 | 329 | 363 | 396 | 446 |
Receivables | 3 | 2 | 1 | 1 | 8 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 16 | 9 | 10 | 9 | 12 |
Total Current Assets | 450 | 340 | 374 | 406 | 466 |
Net Property & Equipment | 43 | 42 | 42 | 43 | 15 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 499 | 388 | 421 | 452 | 484 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 5 | 4 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 13 | 18 | 15 | 21 |
Income Taxes Payable | 2 | 2 | 1 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 21 | 19 | 25 | 21 | 25 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 1 | 0 | |
Minority Interest (Liabilities) | 1,445 | 1,459 | 1,495 | 1,521 | 1,779 |
Total Liabilities | 1,472 | 1,484 | 1,524 | 1,544 | 1,806 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 189 | 53 | 36 | 41 | 31 |
Retained Earnings | -1,162 | -1,149 | -1,140 | -1,134 | -1,353 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -972 | -1,096 | -1,103 | -1,093 | -1,322 |
Total Liabilities & Shareholder's Equity | 499 | 388 | 421 | 452 | 484 |
Total Common Equity | -972 | -1,096 | -1,103 | -1,093 | -1,322 |
Shares Outstanding | 289.60 | 229.30 | 228.10 | 235.40 | 235.10 |
Book Value Per Share | -3.36 | -4.78 | -4.84 | -4.64 | -5.62 |